DOCSLIB.ORG

537.Full.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
537.Full.Pdf Vol. 3, 537-543, April 1997 Clinical Cancer Research 537 A Pilot Clinical/Pharmacological Study of the Protein Kinase C-specific Inhibitor Safingol Alone and in Combination with Doxorubicin Gary K. Schwartz,1 David Ward, Leonard Saltz, INTRODUCTION Ephraim S. Casper, Tara Spiess, Eillen Mullen, PKC2 is a phospholipid-dependent serine/threonine kinase that plays a pivotal role in many of the signal transduction events Jim Woodworth, Robert Venuti, Peter Zervos, related to tumorigenesis. Activation of cell surface receptors by Anne-Mane Storniolo, and David P. Kelsen extracellular molecules such as growth factors and hormones can Department of Medicine, Division of Solid Tumor Oncology, stimulate phosphatidylinositol turnover, leading to elevated levels Gastrointestinal Oncology Section, Memorial Sloan-Kettering Cancer of inositol triphosphate and sn-l,2-diacylglycerol, the endogenous Center, New York, New York 10021 [G. K. S., L. S., E. S. C., T. S., E. M., D. P. K.], and Eli Lilly Research Lab, Indianapolis, Indiana ligand that activates PKC (1 , 2). These extracellular signaling 46285 [D. W., J. W., R. V., P. Z., A-M. S.] molecules, as well as their receptors, are altered in their effect by cellular oncogenes, and diacylglycerol is known to be elevated in cells transformed by ras, sis, and src (3). In addition, activation of ABSTRACT PKC leads to the expression of nuclear proto-oncogenes (e.g., myc, We performed a pilot clinical trial with safingol (L- fos, cis, and fins) associated with cellular proliferation. PKC is threo-dihydrosphingosine), a protein kinase C-specific in- activated by phorbol esters, such as phorbol myristate acetate, hibitor that potentiates the effect of doxorubicin (DOX) in which are potent tumor promoters in mouse skin (4). Increased tumor-bearing animals. Safingol was initially administered tumorigenicity also correlates with overexpression of certain PKC as a 1-h infusion at escalating doses. Fourteen days later, isoforms in Nil-I 3T3 cells inoculated into nude mice (5). The patients received the same dose of safingol in combination involvement of PKC in so many aspects of aberrant growth regu- with a fixed dose of DOX. The combination was repeated at lation suggests that the modulation of PKC activity might be an 3-week intervals. Safingol dose levels ranged from 15 to 120 effective target for anticancer therapy. mg/m2. The plasma levels achieved at the final dose level Safingol (Fig. 1), the L-threo enantiomer of dihydrosphin- were comparable to those associated with potentiation of gosine, is a PKC-specific inhibitor that inhibits PKC enzyme ac- DOX in animals. The mean Cmax and area under the curve tivity in micromolar concentrations (6). In vitro studies of safingol for safingol at the 120 mg/m2 dose level were 1040 ± 196 have demonstrated reversal of multidrug resistance in DOX-resist- ng/ml and 1251 ± 317 mg x h/mI, respectively. The mean ant cell lines (7, 8). Safmgol has also been shown to increase the plasma half-life for safmgol was 3.97 ± 2.51 h, the mean activity of DOX and other chemotherapeutic agents, including estimated clearance was 3140 ± 765 mI/mm, and the mean mitomycin C, by enhancing chemotherapy-induced apoptosis, even volume of distribution was of 995 ± 421 liters. Coadminis- in tumor cell lines that were resistant to chemotherapy by virtue of tration of a fixed dose of DOX did not significantly change a mutation in p53 (6). In vivo, as a single agent, safingol has shown the pharmacokinetics of safingol, nor did increasing doses of little direct antitumor activity. However, in a series of murine tumor safingol significantly affect the pharmacokinetics of DOX. models and human tumor xenografts, safingol has been shown to Minor responses were observed in three patients with pan- significantly modulate the antitumor effect of DOX and cisplatin creatic cancer and one patient with angiosarcoma of the (9, 10). This was achieved without an increase in chemotherapy- induced bone marrow suppression or major organ toxicity (i.e., scalp. This pilot Phase I study indicates that the protein ear or kidney). In these studies, nontoxic serum levels of safingol could kinase C inhibitor safingol can be given safely with 45 be attained at concentrations associated with inhibition of PKC mg/rn2 of DOX at a dose that is potentially pharmacologi- enzyme activity (1 1). cally active without dose-limiting toxicity. Because the in vivo activity of safingol appeared to be greatest when combined with chemotherapy and because this was associated with established serum safingol levels, we per- formed a pilot clinical study of safingol and DOX with phar- macological end points designed to determine whether we could Received 6/4/96; revised 12/18/96; accepted 12/30/96. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to 2 The abbreviations used are: PKC, protein kinase C; DOX, doxorubi- indicate this fact. I To whom requests for reprints should be addressed, at Department of cm; PT, prothrombin; P’FT, partial thromboplastin; CBC, complete Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncol- blood count; DLT, dose-limiting toxicity; HPLC, high-performance ogy Section, Memorial Sloan-Kettering Cancer Center, New York, NY liquid chromatography; AUC, area under the curve; HNTD, highest 10021. Phone: (212) 639-8324; Fax: (212) 717-3320. nontoxic dose. Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 1997 American Association for Cancer Research. 538 Safingol Alone and in Combination with Doxorubicin QH CH3(CH2)1 4AyOH U U- NH2 Day# 1 14 35 Fig. 1 Safingol (L-threo-dihydrosphingosine). I Safingol (infusion over I hour) Doxorubicin (bolus) achieve nontoxic levels of safingol in serum associated with Fig. 2 Treatment scheme of Phase I study for safingol/DOX. Patients chemopotentiation of DOX in animals. were treated in cohorts of three to six patients with safingol on day 1. If there was no acute toxicity, they were again treated with the same dose of safingol on day 14, followed in 1 h by a fixed dose of DOX. If there PATIENTS AND METHODS was no dose-limiting toxicity, they could then be retreated with the same Patients. Patients treated as part of this clinical trial had to combination at the same doses 21 days later (day 35). Subsequent meet the following criteria. All patients had to be 18 years of age cohorts were treated with an increased dose of safingol according to the same treatment scheme and with the DOX dose fixed at all safingol dose with histologically confirmed carcinoma by the Pathology Depart. levels. ment of Memorial Hospital. Patients had to have cancer refractory to standard therapy (or for which there was no standard therapy) and not curable by surgery or radiation therapy. A Karnofsky performance status 60% with a life expectancy of at least 12 measurement of all measurable disease, as well as signs and weeks was required. Previously treated patients were accepted. symptoms. Pretreatment laboratory studies included a CBC, They may not, however, have received myelosuppressive chemo- platelet count, differential, biochemical screening profile, serum therapy or radiation therapy to major bone marrow-containing creatinine, PT, P’fl’, chest X-ray, and urinalysis, and serum areas within the previous 4 weeks (6 weeks for prior nitrosurea or pregnancy test for females. Radiological studies with measure- mitomycin C), and they must have recovered from the marrow ment of the tumor indicator lesion(s) were performed as clini- toxic effects of prior chemotherapy and radiation. cally indicated. Pretreatment gated pool heart scan at rest and a All patients must have had a WBC count 4000/p.l, a total 12-lead EKG were required. neutrophil count 1500/p.l, a platelet count l50,000/p.l, and a Safingol Administration. Safingol is the non-proprie- hemoglobin l0 g/dl, and a normal PT/FIT prior to starting tary name for the L-threo enantiomer of dihydrosphingosine. therapy. Normal renal function (serum creatinine l.5 mg/dl) and The chemical name is (2S,3S)-2-amino-l,3-octadecanediol; the normal hepatic function (serum bilirubin, l.5 mg/dl; serum as- Eli Lilly Research Laboratory code number is SPC-100270; and partate aminotransferase and alkaline phosphatase levels 2.5 safingol is a white to off-white crystalline solid with a molecular times the upper limit of normal) were required. Patients with weight of 301.50. The molecular formula is C18H39N02. documented bone metastases and an elevated alkaline phosphatase Safingol was supplied by Eli Lilly Research Lab (Indian- >25 times the upper limit of normal were eligible for the study if apolis, Indiana) as a 0.5% (5 mg/mI) emulsion, which was all other liver function tests were within the above-specified limits. diluted with 5% dextrose in water to achieve a 0.5 mg/ml A normal resting gated pool heart scan with an ejection fraction solution for administration. The lipid emulsion contained soy- 50% was required. Patients were required to have no prior history bean oil, Pluronic F-68 (NF), cholesterol (NF), a-tocopherol of cardiac arrhythmia requiring therapy (other than chronic atrial (USP), glycerin (USP), water, and HC1. The vials were stored fibrillation). Patients with a history of a myocardial infarction under at 2-8#{176}Cand were for single-use only. The appropriate within 6 months prior to study entry were excluded. Prior DOX amount of safingol was diluted in 5% dextrose in water to treatment was allowed as long as the prior lifetime cumulative dose achieve the desired concentration. The diluted emulsion was ofDOX did not exceed 280 mg/m2. Good peripheral venous access stored at room temperature and was administered within 12 h of was required; otherwise central access via a Mediport or Broviac dilution when stored diluted in either polyvinyl chloride bags or catheter was required.
Load more

Recommended publications
  • Retinamide Increases Dihydroceramide and Synergizes with Dimethylsphingosine to Enhance Cancer Cell Killing
    2967 N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing Hongtao Wang,1 Barry J. Maurer,1 Yong-Yu Liu,2 elevations in dihydroceramides (N-acylsphinganines), Elaine Wang,3 Jeremy C. Allegood,3 Samuel Kelly,3 but not desaturated ceramides, and large increases in Holly Symolon,3 Ying Liu,3 Alfred H. Merrill, Jr.,3 complex dihydrosphingolipids (dihydrosphingomyelins, Vale´rie Gouaze´-Andersson,4 Jing Yuan Yu,4 monohexosyldihydroceramides), sphinganine, and sphin- Armando E. Giuliano,4 and Myles C. Cabot4 ganine 1-phosphate. To test the hypothesis that elevation of sphinganine participates in the cytotoxicity of 4-HPR, 1Childrens Hospital Los Angeles, Keck School of Medicine, cells were treated with the sphingosine kinase inhibitor University of Southern California, Los Angeles, California; D-erythro-N,N-dimethylsphingosine (DMS), with and 2 College of Pharmacy, University of Louisiana at Monroe, without 4-HPR. After 24 h, the 4-HPR/DMS combination Monroe, Louisiana; 3School of Biology and Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, caused a 9-fold increase in sphinganine that was sustained Atlanta, Georgia; and 4Gonda (Goldschmied) Research through +48 hours, decreased sphinganine 1-phosphate, Laboratories at the John Wayne Cancer Institute, and increased cytotoxicity. Increased dihydrosphingolipids Saint John’s Health Center, Santa Monica, California and sphinganine were also found in HL-60 leukemia cells and HT-29 colon cancer cells treated with 4-HPR. The Abstract 4-HPR/DMS combination elicited increased apoptosis in all three cell lines. We propose that a mechanism of N Fenretinide [ -(4-hydroxyphenyl)retinamide (4-HPR)] is 4-HPR–induced cytotoxicity involves increases in dihy- cytotoxic in many cancer cell types.
    [Show full text]
  • Anticancer Effects of Vitamin E Forms and Their Long-Chain Metabolites Via Modulation of Sphingolipid Metabolism Yumi Jang Purdue University
    Purdue University Purdue e-Pubs Open Access Dissertations Theses and Dissertations January 2015 Anticancer Effects of Vitamin E Forms and Their Long-chain Metabolites via Modulation of Sphingolipid Metabolism Yumi Jang Purdue University Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations Recommended Citation Jang, Yumi, "Anticancer Effects of Vitamin E Forms and Their Long-chain Metabolites via Modulation of Sphingolipid Metabolism" (2015). Open Access Dissertations. 1119. https://docs.lib.purdue.edu/open_access_dissertations/1119 This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact [email protected] for additional information. Graduate School Form 30 Updated 1/15/2015 PURDUE UNIVERSITY GRADUATE SCHOOL Thesis/Dissertation Acceptance This is to certify that the thesis/dissertation prepared By Yumi Jang Entitled Anticancer Effects of Vitamin E Forms and Their Long-chain Metabolites via Modulation of Sphingolipid Metabolism For the degree of Doctor of Philosophy Is approved by the final examining committee: Qing Jiang Chair Dorothy Teegarden John R. Burgess Yava Jones-Hall To the best of my knowledge and as understood by the student in the Thesis/Dissertation Agreement, Publication Delay, and Certification Disclaimer (Graduate School Form 32), this thesis/dissertation adheres to the provisions of Purdue University’s “Policy of Integrity in Research” and the use of copyright material. Approved by Major Professor(s): Qing Jiang Approved by: Connie M. Weaver 9/2/2015 Head of the Departmental Graduate Program Date i ANTICANCER EFFECTS OF VITAMIN E FORMS AND THEIR LONG-CHAIN METABOLITES VIA MODULATION OF SPHINGOLIPID METABOLISM A Dissertation Submitted to the Faculty of Purdue University by Yumi Jang In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy December 2015 Purdue University West Lafayette, Indiana ii ACKNOWLEDGEMENTS I owe a debt of gratitude to many people who have made this dissertation possible.
    [Show full text]
  • A Phase I Clinical Trial of Safingol in Combination with Cisplatin in Advanced Solid Tumors
    Published OnlineFirst January 21, 2011; DOI: 10.1158/1078-0432.CCR-10-2323 Clinical Cancer Cancer Therapy: Clinical Research A Phase I Clinical Trial of Safingol in Combination with Cisplatin in Advanced Solid Tumors Mark A. Dickson1, Richard D. Carvajal1, Alfred H. Merrill, Jr.3, Mithat Gonen2, Lauren M. Cane1, and Gary K. Schwartz1 Abstract Purpose: Sphingosine 1-phosphate (S1P) is an important mediator of cancer cell growth and pro- liferation. Production of S1P is catalyzed by sphingosine kinase 1 (SphK). Safingol, (L-threo-dihydro- sphingosine) is a putative inhibitor of SphK. We conducted a phase I trial of safingol (S) alone and in combination with cisplatin (C). Experimental Design: A3þ 3 dose escalation was used. For safety, S was given alone 1 week before the combination. S þ C were then administered every 3 weeks. S was given over 60 to 120 minutes, depending on dose. Sixty minutes later, C was given over 60 minutes. The C dose of 75 mg/m2 was reduced in cohort 4 to 60 mg/m2 due to excessive fatigue. Results: Forty-three patients were treated, 41 were evaluable for toxicity, and 37 for response. The maximum tolerated dose (MTD) was S 840 mg/m2 over 120 minutes C 60 mg/m2, every 3 weeks. Dose- limiting toxicity (DLT) attributed to cisplatin included fatigue and hyponatremia. DLT from S was hepatic enzyme elevation. S pharmacokinetic parameters were linear throughout the dose range with no significant interaction with C. Patients treated at or near the MTD achieved S levels of more than 20 mmol/L and maintained levels greater than and equal to 5 mmol/L for 4 hours.
    [Show full text]
  • Protein Kinase C ␣/␤ Inhibitor Go6976 Promotes Formation of Cell Junctions and Inhibits Invasion of Urinary Bladder Carcinoma Cells
    [CANCER RESEARCH 64, 5693–5701, August 15, 2004] Protein Kinase C ␣/␤ Inhibitor Go6976 Promotes Formation of Cell Junctions and Inhibits Invasion of Urinary Bladder Carcinoma Cells Jussi Koivunen,1 Vesa Aaltonen,1 Sanna Koskela,1,3 Petri Lehenkari,1,3 Matti Laato,4,5 and Juha Peltonen1,2,5 Departments of 1Anatomy and Cell Biology and 2Dermatology, University of Oulu, Oulu, Finland; 3Department of Surgery, Clinical Research Center, University of Oulu, Oulu, Finland; 4Department of Surgery, Turku University Central Hospital, Turku, Finland; and 5Department of Medical Biochemistry, University of Turku, Turku, Finland ABSTRACT drugs in cell cultures and animal models (14–19). Furthermore, isoen- zyme-specific PKC inhibitors seem to be more effective anticancer Changes in activation balance of different protein kinase C (PKC) drugs than broad-spectrum inhibitors, suggesting the role of PKC isoenzymes have been linked to cancer development. The current study activation balance in cancer (20). investigated the effect of different PKC inhibitors on cellular contacts in cultured high-grade urinary bladder carcinoma cells (5637 and T24). Epithelial cells have abundant cell-cell junctions, which have a Exposure of the cells to isoenzyme-specific PKC inhibitors yielded vari- critical role in cell behavior and tissue morphogenesis. The most able results: Go6976, an inhibitor of PKC␣ and PKC␤ isoenzymes, in- important anchoring structures between epithelial cells are adherens duced rapid clustering of cultured carcinoma cells and formation of an junctions and desmosomes. Adherens junctions are composed of increased number of desmosomes and adherens junctions. Safingol, a transmembrane cadherin proteins; ␤-catenin, which attaches to cyto- PKC␣ inhibitor, had similar but less pronounced effects.
    [Show full text]
  • (MAP) Kinase Pathway
    Leukemia (1998) 12, 1843–1850 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 http://www.stockton-press.co.uk/leu REVIEW The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity P Dent1,2, WD Jarvis3, MJ Birrer4, PB Fisher5, RK Schmidt-Ullrich1 and S Grant2,3,6 Departments of 1Radiation Oncology, 3Medicine, 2Pharmacology and Toxicology, and 6Microbiology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA; 4National Cancer Institute, Biomarkers Branch, Division of Clinical Sciences, Rockville, MD; 5Columbia University College of Physicians and Surgeons, Department of Pathology and Urology, New York, NY, USA During the last 10 years, multiple signal transduction pathways terized dual specificity (threonine/tyrosine) protein kinase.4–6 within cells have been discovered. These pathways have been The use of the nomenclature MAPKK/MKK has declined, and linked to the regulation of many diverse cellular events such as proliferation, senescence, differentiation and apoptosis. this enzyme is more frequently referred to as MEK (mitogen This review will focus upon the many roles of signaling by the activated/extracellular regulated kinase). Shortly after the dis- p42/p44 mitogen-activated protein (MAP) kinase pathway. covery of MEK, a second isoform of this enzyme was identified Recent evidence suggests that signaling by the MAP kinase (MEK1 and MEK2).7 MEK1/2 were also found to be regulated pathway can both enhance proliferation by increased by reversible phosphorylation, and within 6 months of the dis- expression of molecules such as cyclin D1, but also cause covery of MEK2, the protein kinase responsible for catalyzing growth arrest by increased expression of molecules such as Cip-1/MDA6/WAF1 MEK1/2 activation was discovered, the proto-oncogene the cyclin kinase inhibitor protein p21 .
    [Show full text]
  • Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy
    cancers Review Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy Preeti Gupta 1, Aaliya Taiyab 1 , Afzal Hussain 2, Mohamed F. Alajmi 2, Asimul Islam 1 and Md. Imtaiyaz Hassan 1,* 1 Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India; [email protected] (P.G.); [email protected] (A.T.); [email protected] (A.I.) 2 Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; afi[email protected] (A.H.); [email protected] (M.F.A.) * Correspondence: [email protected] Simple Summary: Cancer is the prime cause of death globally. The altered stimulation of signaling pathways controlled by human kinases has often been observed in various human malignancies. The over-expression of SphK1 (a lipid kinase) and its metabolite S1P have been observed in various types of cancer and metabolic disorders, making it a potential therapeutic target. Here, we discuss the sphingolipid metabolism along with the critical enzymes involved in the pathway. The review provides comprehensive details of SphK isoforms, including their functional role, activation, and involvement in various human malignancies. An overview of different SphK inhibitors at different phases of clinical trials and can potentially be utilized as cancer therapeutics has also been reviewed. Citation: Gupta, P.; Taiyab, A.; Hussain, A.; Alajmi, M.F.; Islam, A.; Abstract: Sphingolipid metabolites have emerged as critical players in the regulation of various Hassan, M..I. Targeting the Sphingosine Kinase/Sphingosine- physiological processes. Ceramide and sphingosine induce cell growth arrest and apoptosis, whereas 1-Phosphate Signaling Axis in Drug sphingosine-1-phosphate (S1P) promotes cell proliferation and survival.
    [Show full text]
  • Compounds As Lysophosphatidic Acid
    (19) TZZ _ _T (11) EP 2 462 128 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 261/14 (2006.01) C07D 413/04 (2006.01) 21.09.2016 Bulletin 2016/38 A61K 31/42 (2006.01) A61K 31/4427 (2006.01) A61P 11/06 (2006.01) A61P 35/00 (2006.01) (21) Application number: 10807045.9 (86) International application number: (22) Date of filing: 03.08.2010 PCT/US2010/044284 (87) International publication number: WO 2011/017350 (10.02.2011 Gazette 2011/06) (54) COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS VERBINDUNGEN ALS LYSOPHOSPHATIDSÄURE-REZEPTORANTAGONISTEN COMPOSÉS EN TANT QU’ANTAGONISTES DU RÉCEPTEUR DE L’ACIDE LYSOPHOSPHATIDIQUE (84) Designated Contracting States: (74) Representative: Reitstötter Kinzebach AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Patentanwälte GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Sternwartstrasse 4 PL PT RO SE SI SK SM TR 81679 München (DE) (30) Priority: 04.08.2009 US 231282 P (56) References cited: WO-A1-2004/031118 WO-A2-2009/011850 (43) Date of publication of application: US-A1- 2003 114 505 US-A1- 2006 194 850 13.06.2012 Bulletin 2012/24 • YAMAMOTO, T. ET AL.: ’Synthesis and (73) Proprietor: Amira Pharmaceuticals, Inc. evaluation of isoxazole derivatives as Princeton, NJ 08543 (US) lysophosphatidic acid (LPA) antagonists’ BIOORGANIC & MEDICINAL CHEMISTRY (72) Inventors: LETTERS vol. 17, 2007, pages 3736 - 3740, • HUTCHINSON, John, Howard XP022114572 San Diego • OHTA, H. ET AL.: ’Ki16425, a Subtype-Selective CA 92103 (US) Antoganist for EDG-Family Lysophosphatidic • SEIDERS, Thomas, Jon AcidReceptors’ MOLECULAR PHARMACOLOGY San Diego vol.
    [Show full text]
  • Protein Kinase C: a Target for Anticancer Drugs?
    Endocrine-Related Cancer (2003) 10 389–396 REVIEW Protein kinase C: a target for anticancer drugs? HJ Mackay and CJ Twelves Department of Medical Oncology, Cancer Research UK Beatson Laboratories, Alexander Stone Building, Switchback Road, Glasgow G61 1BD, UK (Requests for offprints should be addressed to C Twelves; Email: [email protected]) (HJ Mackayis now at Department of Drug Development, Medical Oncology,Princess Margaret Hospital, Toronto, Ontario, Canada) (CJ Twelves is now at Tom Connors Cancer Research Centre, Universityof Bradford, Bradford, UK) Abstract Protein kinase C (PKC) is a familyof serine/threonine kinases that is involved in the transduction of signals for cell proliferation and differentiation. The important role of PKC in processes relevant to neoplastic transformation, carcinogenesis and tumour cell invasion renders it a potentiallysuitable target for anticancer therapy. Furthermore, there is accumulating evidence that selective targeting of PKC mayimprove the therapeutic efficacyof established neoplastic agents and sensitise cells to ionising radiation. This article reviews the rationale for targeting PKC, focuses on its role in breast cancer and reviews the preclinical and clinical data available for the efficacyof PKC inhibition. Endocrine-Related Cancer (2003) 10 389–396 Introduction anchoring proteins (Csuki & Mochley-Rosen 1999, Way et al. 2000). The protein kinase C (PKC) family consists of at least 12 The phospholipid diacylglycerol (DAG) plays a central isozymes that have distinct and in some cases opposing roles role in the activation of PKC by causing an increase in the in cell growth and differentiation (Blobe et al. 1994, Ron & affinity of PKCs for cell membranes which is accompanied Kazanietz 1999).
    [Show full text]
  • Cycloserine and Threo-Dihydrosphingosine Inhibit TNF-A-Induced Cytotoxicity: Evidence for the Importance of De Novo Ceramide Synthesis in TNF-A Signaling
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1643 (2003) 1–4 www.bba-direct.com Rapid report Cycloserine and threo-dihydrosphingosine inhibit TNF-a-induced cytotoxicity: evidence for the importance of de novo ceramide synthesis in TNF-a signaling Sybille G. E. Meyer*, Herbert de Groot Institut fu¨r Physiologische Chemie, Universita¨tsklinikum Essen, Hufelandstrasse 55, D-45147 Essen, Germany Received 2 July 2003; accepted 9 October 2003 Abstract Measuring the cell death induced by tumor necrosis factor (TNF-a) in L929 cells, we discovered for the first time that L-cycloserine, an established inhibitor of serine palmitoyltransferase, as well as DL-threo-dihydrosphingosine (threo-DHS, threo-sphinganine) significantly protected against TNF-a-induced cytotoxicity. Under the same conditions sphingosine and DL-erythro-dihydrosphingosine (erythro-DHS) did not change TNF-a-induced cytotoxicity, thus underlining the specificity of threo-DHS. In serine-labeled cells, newly (de novo) synthetized labeled ceramide was significantly diminished by threo-DHS alone or together with TNF-a, which makes the (dihydro) ceramide synthase the likely target of threo-DHS. These results suggest the decisive role of ceramide de novo synthesis in TNF signaling. D 2003 Elsevier B.V. All rights reserved. Keywords: Ceramide de novo synthesis; Safingol; Sphinganine; Sphingosine; Threo-dihydrosphingosine; Tumor necrosis factor-a (TNF-a) Tumor necrosis factor-a (TNF-a) is a pleiotropic cyto- ceramide was only shown in TNF/cycloheximide-induced kine produced mainly by macrophages. It mediates inflam- cell death in cerebral endothelial cells using Fumonisin B1 mation and regulates immune function by triggering the [9].
    [Show full text]
  • Overexpression of Ecto-5′-Nucleotidase Promotes P
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 52 (1997), pp. 953—961 Overexpression of ecto-5 '-nucleotidase promotes P-glycoprotein expression in renal epithelial cells SEVERINE LEDOUX, CHRISTINE LEROY, GRALDINE SIEGFRIED, DOMINIQUE PRIE, PHILIPPE MOULLIER, and GJRARD FRIEDLANDER INSERM U 426, and Department of Physiology, Faculté Xavier-Bichat, Université Denis-Diderot, Paris, and Laboratoire de Thérapie Genique, CHI] Hôtel-Dieu, Nantes, France Overexpression of ecto-5'-nucleotidase promotes P-glycoprotein ex- doxorubicin and epidophyllotoxin [1, 2] out of the tumoral cells pression in renal epithelial cells. P-glycoprotein (P-gp), responsible for and thus prevents drug intracellular accumulation and toxicity. multidrug resistance (MDR) of tumoral cells, is also expressed in apical P-gp has been detected in a variety of normal cells including membranes of normal epithelial cells, among which are proximal tubular cells. Ecto-5'-nucleotidase (5'Nu), co-located with P-gp in renal brush epithelial cells from small intestine, colon, biliary canalicules and border membranes, could be instrumental in the expression of MDR kidney proximal tubules [11.Inepithelial cells, especially in renal phenotype. P-gp activity [assessed by rhodamine 123 (R123) and [3H]vin- proximal tubular cells, P-gp has been detected in apical mem- blastine (3H-VBL) accumulation] was evaluated in MDCK cell lines in branes [1]. This localization suggests a role of P-gp in the which human 5'Nu was expressed at different levels after retroviral infection: MDCK-5'NU/—- cells with a low 5'Nu activity <2 extrusion of molecules to the tubular lumen, but the precise pmol/mg protein/mm) and MDCK-5'NU/+ cells, which expressed a high function and the endogenous substrate(s) of P-gp in normal cells level of 5'Nu (Vr,,ax 150 18.5pmol/mg protein/mm).
    [Show full text]
  • Sphingolipids Standards and Additional Research Tools
    Sphingolipids Standards and Additional Research Tools Sphingolipids reside in the outer leaflet of the cell membrane where they modulate Inhibitors Available uoro Pamitic Acid (90380) Locai cyoA Sytetae cell-cell interactions andTriaci (10007448)can regulate differentiation, proliferation, and programmed cell death. Ceramide is the intermediateLSerie PamitoyoA in the formation of multiple types of sphingolipids Myrioci (63150) Serie Pamitoytraerae L-Cycoerie (17780) that mediate a wide range of biological activities.1-Amiodecyidee bis-Phosphonic To Acid (sodiumhelp salt) (13583) you study distinct aspects EtaoamiePoate Benztropine (mesylate) (16214) 3-Ketoiaie cis-Flupenthixol (hydrochloride) (17634) C16-Fatty Aldehyde GW 4869 (hydrochloride hydrate) (13127) of this important lipid signaling pathway, CaymanTomatidine (hydrochloride) (16938)carries many different sphingolipid 3-Ketoiaie eductae Fumoii 1 (62580) GM4 DN (19939) Fumoii 2 (13227) Fumoii 3 (20434) standards as well as inhibitorsP053 for the various enzymes driving key events in Siaie Siomyeiae Siaidae Siomyei Siomyei Sytae sphingolipid metabolism. Ceramide Sytae Gaactosyceramide Suatide Gaactoyceramide Suotraerae Feretiide (17688) Ceramideβ aactoytraerae-Gaactoyceramidae D609 (potassium salt) (13307) Neacyae Diydroceramide 2-Acetyl-5-tetrahydroxybutyl Imidazole (13222) SP yae Gaactoyioie Diydroceramide eaturae Sphingosine-1-Phosphate (S1P) NP (13858) P-Deoyoirimyci (10010332) Codurito eoide (15216) CAY10621 (13371) Primary Pathways for N,N-Dimethylsphingosine (d18:1) (62575)
    [Show full text]
  • The Role of Reactive Oxygen Species and Autophagy in Safingol-Induced
    Citation: Cell Death and Disease (2011) 2, e129; doi:10.1038/cddis.2011.12 & 2011 Macmillan Publishers Limited All rights reserved 2041-4889/11 www.nature.com/cddis The role of reactive oxygen species and autophagy in safingol-induced cell death L-U Ling1, K-B Tan1, H Lin1 and GNC Chiu*,1 Safingol is a sphingolipid with promising anticancer potential, which is currently in phase I clinical trial. Yet, the underlying mechanisms of its action remain largely unknown. We reported here that safingol-induced primarily accidental necrotic cell death in MDA-MB-231 and HT-29 cells, as shown by the increase in the percentage of cells stained positive for 7-aminoactinomycin D, collapse of mitochondria membrane potential and depletion of intracellular ATP. Importantly, safingol treatment produced time- and concentration-dependent reactive oxygen species (ROS) generation. Autophagy was triggered following safingol treatment, as reflected by the formation of autophagosomes, acidic vacuoles, increased light chain 3-II and Atg biomarkers expression. Interestingly, scavenging ROS with N-acetyl-L-cysteine could prevent the autophagic features and reverse safingol-induced necrosis. Our data also suggested that autophagy was a cell repair mechanism, as suppression of autophagy by 3-methyladenine or bafilomycin A1 significantly augmented cell death on 2-5 lM safingol treatment. In addition, Bcl-xL and Bax might be involved in the regulation of safingol-induced autophagy. Finally, glucose uptake was shown to be inhibited by safingol treatment, which was associated with an increase in p-AMPK expression. Taken together, our data suggested that ROS was the mediator of safingol-induced cancer cell death, and autophagy is likely to be a mechanism triggered to repair damages from ROS generation on safingol treatment.
    [Show full text]